Suresh Pola MD (He/Him)
Inflammatory Bowel Disease
Staff Physician Cleveland Clinic
Join to View Full Profile
3700 Park East DrSuite 100Beachwood, OH 44122
Phone+1 440-461-2550
Fax+1 858-552-4327
Dr. Pola is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Suresh Pola, MD, is a staff gastroenterologist and Director of Inflammatory Bowel Diseases at Cleveland Clinic’s Consultants in Gastroenterology practice. He is board certified in gastroenterology and internal medicine, with advanced IBD training including intestinal ultrasound. Dr. Pola previously served as the first IBD physician lead at Kaiser Permanente Southern California.
Education & Training
University of California (San Diego) Medical CenterFellowship, Gastroenterology, 2009 - 2012
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
Case Western Reserve University School of MedicineClass of 2006
Certifications & Licensure
CA State Medical License 2008 - 2027
OH State Medical License 2025 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Physician of the Year Crohns and Colitis Foundation San Diego, 2019
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Publications & Presentations
PubMed
- 18 citationsImmunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.Robert Battat, Dana J. Lukin, Ellen Scherl, Suresh Pola, Anand Kumar
Inflammatory Bowel Diseases. 2021-08-19 - 3 citationsRetrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States.Joshua T Smith, Fernando S Velayos, Fang Niu, Vincent Liu, Thomas Delate
Crohn's & Colitis 360. 2021-07-01 - 10 citationsEffectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the U...Stephanie L Ho, Fang Niu, Suresh Pola, Fernando S Velayos, Xian Ning
Biodrugs. 2020-06-01
Press Mentions
The AMA Does Not Speak for UsDecember 9th, 2016
Other Languages
- French, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
